Chronic Liver Disease Questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients

Hepatology Research

Volumn 45, Issue 9, 2015, Pages 994-1003

  Hirano, Hirotaka ^a   Saito, Masaya ^a   Yano, Yoshihiko ^a   Momose, Kenji ^a   Yoshida, Masaru ^a   Tanaka, Atsushi ^b   Azuma, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Health related quality of life; L carnitine; Neurophysiological test; Nomogram; Taurine; Zinc

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMMONIA; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CARNITINE; CHLORINE; CHOLESTEROL; CHOLINESTERASE; CREATINE KINASE; CREATININE; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; PHOSPHORUS; POTASSIUM; SODIUM; TRIACYLGLYCEROL; UNINDEXED DRUG; UREA; URIC ACID;

ADULT; AGED; ARTICLE; BLOCK DESIGN TEST; CHRONIC LIVER DISEASE QUESTIONNAIRE; CHRONIC LIVER DISEASE QUESTIONNAIRE ABDOMINAL SYMPTOM; CHRONIC LIVER DISEASE QUESTIONNAIRE ACTIVITY; CHRONIC LIVER DISEASE QUESTIONNAIRE EMOTIONAL FUNCTION; CHRONIC LIVER DISEASE QUESTIONNAIRE FATIGUE; CHRONIC LIVER DISEASE QUESTIONNAIRE SYSTEMIC SYMPTOM; CHRONIC LIVER DISEASE QUESTIONNAIRE WORRY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DIGIT SYMBOL TEST; FEMALE; FIGURE POSITION TEST; HEPATIC ENCEPHALOPATHY; HIGH RISK PATIENT; HUMAN; JAPANESE (PEOPLE); LABORATORY TEST; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MINIMAL HEPATIC ENCEPHALOPATHY; NEUROPSYCHOLOGICAL TEST; NUMBER CONNECTION TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; REACTION TIME TEST; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 84941005831     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12442     Document Type: Article

References (47)

1. Zhou YQ, Chen SY, Jiang LD, et al. Development and evaluation of the quality of life instrument in chronic liver disease patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol 2009; 24: 408-15.
2. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000; 95: 2029-34.
3. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-23.
4. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.
5. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903-9.
6. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-45.
7. Bajaj JS, Saeian K, Hafeezullah M, Hoffmann RG, Hammeke TA. Patients with minimal hepatic encephalopathy have poor insight into their driving skill. Clin Gastroenterol Hepatol 2008; 6: 1135-9.
8. Kato A, Kato M, Ishii H, et al. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria-multicenter collaborative study in Japanese. Hepatol Res 2004; 30: 71-8.
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
10. Narahara Y, Kanazawa H, Fukuda T, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46: 78-85.
11. Shimbo K, Kubo S, Harada Y, et al. Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. Biomed Chromatogr 2010; 24: 683-91.
12. Michitaka K, Tokumoto Y, Uesugi K, et al. Neuropsychiatric dysfunction in patients with chronic hepatitis and liver cirrhosis. Hepatol Res 2008; 38: 1069-75.
13. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
14. Mahmood S, Kida T, Izumi A, et al. Assessment of health related quality of life in chronic liver disease patients using the Japanese versions of CLDQ and SF-36. Open Gastroenterol J 2008; 2: 57-63.
15. Román E, Córdoba J, Torrens M, et al. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 2011; 106: 476-82.
16. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-5.
17. Moscucci F, Nardelli S, Pentassuglio I, et al. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. Liver Int 2011; 31: 1505-10.
18. Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010; 138: 2332-40.
19. Marić D, Klasnja B, Filipović D, Brkić S, Ruzić M, Bugarski V. Minimal hepatic encephalopathy in patients with decompensated liver cirrhosis. Acta Clin Croat 2011; 50: 375-80.
20. Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. J Hepatol 2000; 32: 748-53.
21. Román E, Córdoba J, Torrens M, Guarner C, Soriano G. Falls and cognitive dysfunction impair health-related quality of life in patients with cirrhosis. See comment in PubMed Commons belowEur J Gastroenterol Hepatol 2013; 25: 77-84.
22. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007; 47: 67-73.
23. Kharbanda PS, Saraswat VA, Dhiman RK. Minimal hepatic encephalopathy: diagnosis by neuropsychological and neurophysiologic methods. Indian J Gastroenterol 2003; 22: S37-41.
24. Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 629-35.
25. Kato A, Tanaka H, Kawaguchi T, et al. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: a preliminary, prospective, open-label study. Hepatol Res 2013; 43: 452-8.
26. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
27. Ferrer M, Córdoba J, Garin O, et al. Validity of the Spanish version of the chronic liver disease questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl 2006; 12: 95-104.
28. Häuser W, Schnur M, Steder-Neukamm U, Muthny FA, Grandt D. Validation of the German version of the chronic liver disease questionnaire. Eur J Gastroenterol Hepatol 2004; 16: 599-606.
29. Rucci P, Taliani G, Cirrincione L, et al. Validity and reliability of the Italian version of the chronic liver disease questionnaire (CLDQ-I) for the assessment of health-related quality of life. Dig Liver Dis 2005; 37: 850-60.
30. Wunsch E, Szymanik B, Post M, Marlicz W, Mydłowska M, Milkiewicz P. Minimal hepatic encephalopathy does not impair health-related quality of life in patients with cirrhosis: a prospective study. Liver Int 2011; 31: 980-4.
31. Wang JY, Zhang NP, Chi BR, et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol 2013; 19: 4984-91.
32. Bao ZJ, Qiu DK, Ma X, et al. Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol 2007; 13: 3003-8.
33. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59.
34. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 37-41.
35. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9.
36. Guerit JM, Amantini A, Fischer C, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 789-96.
37. Weissenborn K, Scholz M, Hinrichs H, Wiltfang J, Schmidt FW, Künkel H. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol 1990; 75: 289-95.
38. Weissenborn K Minimal hepatic encephalopathy: a permanent source of discussion. Hepatology 2002; 35: 494-6.
39. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME trial). Am J Gastroenterol 2011; 106: 307-16.
40. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008; 53: 3018-25.
41. Dolezal V, Tucek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J Neurochem 1981; 36: 1323-30.
42. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41: 1726-32.
43. Malaguarnera M, Pistone G, Astuto M, et al. L-carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003; 21: 271-5.
44. Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutiérrez T, Villegas-López FA, Méndez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013; 12: 74.
45. Butterworth RF. Taurine in hepatic encephalopathy. Adv Exp Med Biol 1996; 403: 601-6.
46. Tuerk MJ, Fazel N. Zinc deficiency. Curr Opin Gastroenterol 2009; 25: 136-43.
47. Sergeeva OA, Fleischer W, Chepkova AN, et al. GABAA-receptor modification in taurine transporter knockout mice causes striatal disinhibition. J Physiol 2007; 585: 539-48.